Evidence Level
Sea Moss research primarily focuses on its compositional and preclinical properties, with limited human clinical trials examining its effects. The most robust evidence pertains to its iodine content, as seaweeds are recognized natural sources of iodine, crucial for thyroid function (Teas et al., 2004; Zava & Zava, 2011). A comprehensive mineral analysis by Pereira (2011) confirmed that red seaweeds, including sea moss, contain significant levels of essential minerals. Additionally, the bioactive polysaccharides in sea moss, such as carrageenans, have shown promise in vitro: Liu et al. (2015) demonstrated prebiotic effects on gut bacteria, while Leibbrandt et al. (2010) found that iota-carrageenan inhibits influenza virus entry into cells.
However, some aspects of sea moss remain controversial or unverified. The claim of containing 92 minerals lacks peer-reviewed support, and carrageenan has raised safety concerns. McKim (2014) reviewed carrageenan's safety, concluding that food-grade carrageenan is safe at typical dietary levels but noting potential risks from degraded forms like poligeenan. Despite these findings, a significant research gap persists due to the near-absence of randomized controlled trials in humans assessing sea moss supplementation for specific health outcomes.
Available references include studies on iodine content variability (Teas et al., 2004), mineral composition (Pereira, 2011), prebiotic effects (Liu et al., 2015), antiviral activity (Leibbrandt et al., 2010), and carrageenan safety (McKim, 2014). These studies highlight the potential benefits of sea moss while also emphasizing the need for further research to confirm its efficacy and safety in human populations.